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OBJECTIVE: During the neonatal and infancy periods, some chronic liver diseases may lead to progressive hepatic
fibrosis, which is a condition that can ultimately result in the loss of organ function and severe portal hypertension
necessitating hepatic transplantation. In a previous report, pharmacological interventions were demonstrated to
modulate hepatic fibrosis induced by bile duct ligation in young rats. The administration of pentoxifylline or
prednisolone, or the combination of both, resulted in reduced fibrogenesis in portal spaces. The objectives of the
present study were to evaluate the expression of transforming growth factor b and vascular endothelial growth
factor after bile duct ligation in young rats and to assess the effect of those same drugs on cytokine expression.
METHODS: In this experimental study, 80 young rats (21 or 22 days old) were submitted either to laparotomy and
common bile duct ligation or to sham surgery. The animals were allocated into four groups according to surgical
procedure, and the following treatments were administered: (1) common bile duct ligation + distilled water, (2) sham
surgery + distilled water, (3) common bile duct ligation + pentoxifylline, or (4) common bile duct ligation +
prednisolone. After 30 days, a hepatic fragment was collected from each animal for immunohistochemical analysis
using monoclonal antibodies against transforming growth factor b and vascular endothelial growth factor. Digital
morphometric and statistical analyses were performed.
RESULTS: The administration of pentoxifylline reduced the transforming growth factor b-marked area and the
amount of transforming growth factor b expressed in liver tissue. This effect was not observed after the
administration of prednisolone. There was a significant reduction in vascular endothelial growth factor expression
after the administration of either drug compared with the non-treatment group.
CONCLUSIONS: The administration of pentoxifylline to cholestatic young rats resulted in the diminished expression
of transforming growth factor b and vascular endothelial growth factor in liver tissue. The administration of steroids
resulted in the diminished expression of vascular endothelial growth factor only. These pathways may be involved in
hepatic fibrogenesis in young rats submitted to bile duct ligation and exposed to pentoxifylline or prednisolone.
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INTRODUCTION
Cholestatic disorders are responsible for chronic hepatic
failure in a significant number of patients during infancy. In
the neonatal period, the most frequent cholestatic disease
requiring liver transplantation is biliary atresia, a condition
for which the pathogenesis is not yet fully understood but
that is absolutely fatal if left untreated (1).
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Since the 1970s, some authors have suggested that the
administration of corticosteroids may promote better late
outcomes of biliary atresia in children who undergo Kasai’s
portoenterostomy (2-4). In recent years, some results of this
new strategy have been published, but the available data
still do not clearly demonstrate a difference in jaundice-free
survival and a reduced need for early liver transplantation
(5-7). Other potentially antifibrogenic drugs have also been
experimentally tested in animals, including pentoxifylline
(PTX), a phosphodiesterase inhibitor already used in clinical
practice for the treatment of arterial insufficiency (8-10).
Some studies have demonstrated the inhibition of inflam-
matory cytokines, such as tumor necrosis factor a, trans-
forming growth factor b, and interleukins (ILs) 1, 6, and 8
(11,12). Other studies have failed to demonstrate this effect
in animal models (9,13). Therefore, no consensus exists
regarding the role of PTX in the inflammatory and
fibrogenic cascades.
Our group has been investigating the effects of antifibro-
genic drugs over the last few years, with a particular focus
on their effects in growing animals. We reported our initial
results in 2009 after developing a model to study portal
fibrosis secondary to biliary obstruction in young rats (14-
15). We concluded that hepatic fibrosis induced by bile duct
ligation in young rats could be modulated by pharmacologic
interventions. The administration of pentoxifylline or pre-
dnisolone (PRED), or the combination of both, resulted in
diminished collagen-filled areas in the portal spaces. We
have continued this work and now present an immunohis-
tochemical analysis of the expression of transforming
Figure 1 - Digitized slide microphotography showing Anti-VEGF immunohistochemical staining. From left to right: CBDL (100x
magnification), PTX (200x magnification), and PRED (200x magnification).
Figure 2 - Ratio between the anti-TGFb-stained area (mm2) and total area (mm2): PTX x CBDL, p=0.032; PRED x CBDL, p=0.089. The
numbers in the graphic are outliers.
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growth factor b (TGFb) and vascular endothelial growth
factor (VEGF) after bile duct ligation in young rats and the
influence of these drugs on cytokine expression.
METHODS
This study was approved by the Ethical Committee for
Research Project Analysis of our institution and was
conducted according to international guidelines regarding
the use of laboratory animals. All operative procedures
were performed by the same surgeon.
Surgical procedures
Young (21- to 22-day-old) Wistar rats were submitted to
common bile duct ligation (CBDL) as described in a
previous report (15). Under ether anesthesia, a median
laparotomy was performed, and the common bile duct was
ligated and divided twice using 6.0 monofilament nylon
ligation. The sham surgery (SHAM) consisted of the
laparotomy and exposure of the hepatic hilum without
duct ligation. The animals were randomly allocated into
four groups (20 animals per group) according to the surgical
procedure and were administered a solution as follows: 1)
CBDL + distilled water; 2) SHAM + distilled water; 3) CBDL
+ PTX 10 mg/kg per day; or 4) CBDL + PRED 3 mg/kg per
day.
The solutions were administered once a day via nasogas-
tric tubing under sedation. The drug doses per kilogram
were similar to those used in humans in the clinical setting.
After 30 days, cardiorespiratory arrest was induced by the
inhalation of anesthesia (ether gas chamber at a high
concentration). The animals were rapidly weighed and
submitted to midline incision for the harvesting of a 1-cm3
hepatic fragment from the left lobe.
Histological analysis
The hepatic fragments were processed according to standard
techniques (3-mm-thick sections of paraffin-embedded material)
to obtain two slides for each animal. The slides were included in
3-aminopropyl-trietoxi-silano, and immunohistochemical reac-
tions followed the biotin-streptavidin-peroxidase protocol. The
primary antibodies were as follows: monoclonal anti-mouse
TGFb IgG (sc-52893, Santa Cruz Biotechnology, USA) and
monoclonal anti-mouse VEGF IgG (sc-7269, Santa Cruz
Biotechnology, Santa Cruz, CA, USA). The secondary antibody
was the Vectastain anti-mouse ABCkitTM (Vector Laboratories,
Burlingame, CA, USA) for both reactions. The protein block was
accomplished with methanol/azide for the TGFb slides and
with the NovocastraTM system (Leica Microsystems, Milton
Keynes, England, UK) for the VEGF reactions. The slides were
analyzed under a Leica DMR microscope and digitized with
Panoramic Scan MidiTM (3DHistech, Hungary Software,
Budapest, Hungary).
Morphometric analysis
Aleatory areas were delineated on each digitized slide
and processed with the aid of the software Image Pro-Plus
4.5.0.29 Windows XP version (Media Cybernetics Inc.). After
Figure 3 - Integrated optical density (IOD). Anti-TGFb stained slides: PTX x CBDL, p=0.032; PRED x CBDL, p=0.231. The numbers in the
graphic are outliers.
CLINICS 2012;67(12):1455-1461 Portal fibrogenesis and biliary obstruction
Andrade WC et al.
1457
image acquisition, the software was calibrated to automate
the cytokine (TGFb or VEGF) identification. Several mea-
surements were performed: total area, cytokine-marked
area (area +), integrated optical density (IOD; antibody color
intensity measure, which reflects the amount of cytokine
present in the tissue), antibody distribution or proportion
(area +/total area), and mean density (IOD/area +).
Statistical analysis
Comparisons of the data between groups were performed
using the software SPSS version 18.0 for Windows (SPSS
Inc., Chicago, IL). As the data had a normal distribution, the
analysis of variance and Tukey’s post hoc test were applied
to test for differences between groups. The hypothesis of
sample equality was rejected for p,0.05.
RESULTS
Descriptive analysis
TGFb expression
1. Sham: no hepatocyte presentation, expression in
endothelial and hepatic stellate cells;
2. CBDL: mild expression in periportal hepatocytes, no
expression in the biliary epithelium;
3. PRED: irregular hepatocyte expression in different areas
of the hepatic lobule, clear presentation in endothelial
and hepatic stellate cells;
4. PTX: less intense expression in hepatocytes and endothe-
lial cells than in the PRED group.
VEGF expression: All groups exhibited VEGF expression
in hepatocytes, endothelial and hepatic stellate cells and the
biliary epithelium. Only fibrous areas were not stained
(Figure 1).
Morphometric analysis
TGFb expression
Validating the findings of the descriptive analysis, the
administration of pentoxifylline (PTX) to growing rats
reduced the size of the cytokine-marked area (Figure 2)
and the amount of TGFb expressed in liver tissue (Figure 3),
as reflected by the integrated optical density (IOD). These
effects were not observed after the administration of
prednisolone (Figures 2 and 3).
VEGF expression
The reduction in the expression of VEGF after the
administration of both drugs was quite remarkable. The
distribution of this cytokine (Figure 4) was reduced in the
PTX and PRED groups relative to the CBDL group (p,0.001).
Although the decrease in the absolute amount of cytokine in
the PRED group, as revealed by the IOD index, did not reach
statistical significance (p= 0.195, Figure 5) compared with the
CBDL group, when transformed into the mean density (ratio
Figure 4 - Ratio between the anti-VEGF-stained area (mm2) and total area (mm2): PTX x CBDL, p,0.001; PRED x CBDL, p,0.001. The
number in the graphic is an outlier.
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between the IOD and positive area), a significant decrease
was revealed (p= 0.001, Figure 6).
DISCUSSION
Regarding the treatment of biliary atresia in children,
clinicians have been empirically prescribing steroids imme-
diately post-Kasai surgery since the 1980s (16-18). In the
wake of progressive liver disease following bile duct
obstruction, steroids are hypothesized to suppress inflam-
mation and promote bile flow (19), but recent clinical
reports have been controversial (20,21) and have failed to
clearly demonstrate an actual long-term benefit (i.e.,
transplant-free survival) of the adjuvant use of steroids
after portoenterostomy.
Another medication included in this study was pentox-
ifylline (PTX), a potentially antifibrogenic drug (9-13,22).
Classified as a nonspecific phosphodiesterase inhibitor, this
drug has already been incorporated into the clinical setting
for the treatment of chronic occlusive arterial disease
because of its oxygen transport-enhancing effect. As
phosphodiesterases regulate the intracellular levels of cyclic
nucleotides (cyclic adenosine monophosphate and cyclic
guanosine monophosphate), their inhibition can affect
several processes, such as apoptosis, muscle contraction,
cellular differentiation, migration, and proliferation (23-25).
Specifically regarding hepatic fibrogenesis, since 1993, there
have been some publications demonstrating that PTX can
decrease the activation and proliferation of stellate cells and
downregulate the production of IL-1, IL-6, and tumor
necrosis factor a (all proinflammatory cytokines) (26).
In a previous report (15), we revealed that the adminis-
tration of a steroid and pentoxifylline to recently weaned
rats submitted to biliary obstruction could promote a
reduction in the collagen-filled areas in liver tissue,
indicating a potential mechanism for the pharmacological
modulation of cholestasis-induced portal fibrosis. We
believe that the use of growing animals, rather than adults,
as experimental models may more accurately represent the
histological abnormalities found in newborns or children
affected by cholestasis (14).
The exact mechanisms involved in portal biliary fibrosis
in young animals are not completely understood. The
present investigation was conducted to contribute to the
elucidation of the following specific question: how is hepatic
collagen deposition secondary to biliary obstruction affected
by the administration of steroids and PTX?
Among other cytokines, TGFb and VEGF appear to
actively participate in the processes of inflammatory cell
recruitment and hepatic fibrogenesis and the mediation of
the adaptive proliferative response of cholangiocytes to
cholestasis (27-29). Are these cytokines affected by the
administration of steroids and PTX?
In this model, we were able to demonstrate, through
immunohistochemical analyses, that VEGF expression was
substantially reduced following exposure to steroids and
PTX. However, only PTX appeared to affect the liver tissue
expression of TGFb. We failed to demonstrate a significant
Figure 5 - Integrated optical density (IOD). Anti-VEGF-stained slides: PTX x CBDL, p,0.001; PRED x CBDL, p=0.195.
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difference in this expression after the administration of
prednisolone. The impairment in the pathways of these two
cytokines after the administration of PTX to these growing
animals may explain the slightly more accentuated reduc-
tion in collagen deposition observed in our previous report
compared with the PRED group.
Obviously, other cells, cytokines, signaling pathways, and
mechanisms are involved in a process as complex as hepatic
fibrogenesis. Therefore, subsequent experimental and clin-
ical studies should be conducted to confirm the benefits of
exposing jaundiced children to these medications, with the
aim of reducing hepatic fibrosis and the need for liver
transplantation.
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